[TYPE THE COMPANY NAME]
LML4801 Assignment
2 (COMPLETE
GUIDELINE) Semester
1 2025 - DUE 24 April
2025
NO PLAGIARISM
[Pick the date]
[Type the abstract of the document here. The abstract is typically a short summary of the contents of
the document. Type the abstract of the document here. The abstract is typically a short summary of
the contents of the document.]
, LML4801 Assignment 2 (COMPLETE GUIDELINE) Semester 1 2025 - DUE 24
April 2025; 100% TRUSTED Complete, trusted solutions and explanations.
Ensure your success with us....
Scenario Peter works for Pharmabayu Inc in South Africa, as a researcher
testing various dosage regimes of known and new pharmaceutical
compounds. While on holiday, he devises a new dosage regime for an
existing pharmaceutical compound known to be used in cardiac arrythmia
management medicine since 2004. Pharmabayu applies for a patent for
which the patent claim for the patent (granted on 5 August 2023) reads as
follows: ‘The use of the compound (maxorevo) for the manufacture of a
medicament in an oral dosage form for the treatment of cardiac disorders for
administration no more than once daily for at least seven consecutive days,
where said compound has a plasma concentration half-life of 12 hours or less
when orally administered to a human patient, wherein the cardiac disorder is
arrhythmia, and wherein the oral dosage form is a rapid-release tablet.’ A
rival pharmaceutical firm, R.D. Gen, decides to apply for the revocation of
this patent to bring their own cardiac arrythmia medicine (which also makes
use of maxorevo) to market. The maxorevo compound was first identified in
March 2001. Outline the potentially viable revocation grounds that R.D. Gen
might rely on for this application and comment on the likelihood of success
for each ground.
To assess R.D. Gen’s grounds for revoking Pharmabayu Inc.’s patent in South Africa, it’s
necessary to consider the requirements for patentability under the South African Patents Act 57
of 1978 and applicable case law. The key grounds for revocation of a patent under section 61(1)
of the Patents Act include lack of novelty, lack of inventive step, non-patentable subject
matter, lack of utility, and prior use/disclosure.
Below is a structured analysis of the potentially viable revocation grounds that R.D. Gen might
rely upon and the likelihood of success for each.
1. Lack of Novelty – Section 61(1)(c)
Explanation: A patent lacks novelty if the invention was disclosed to the public anywhere in the
world before the priority date (in this case, before 5 August 2023, or the filing date).
Application to the Scenario:
The compound maxorevo was identified as early as March 2001.
It has been used in cardiac arrhythmia treatment since 2004.
LML4801 Assignment
2 (COMPLETE
GUIDELINE) Semester
1 2025 - DUE 24 April
2025
NO PLAGIARISM
[Pick the date]
[Type the abstract of the document here. The abstract is typically a short summary of the contents of
the document. Type the abstract of the document here. The abstract is typically a short summary of
the contents of the document.]
, LML4801 Assignment 2 (COMPLETE GUIDELINE) Semester 1 2025 - DUE 24
April 2025; 100% TRUSTED Complete, trusted solutions and explanations.
Ensure your success with us....
Scenario Peter works for Pharmabayu Inc in South Africa, as a researcher
testing various dosage regimes of known and new pharmaceutical
compounds. While on holiday, he devises a new dosage regime for an
existing pharmaceutical compound known to be used in cardiac arrythmia
management medicine since 2004. Pharmabayu applies for a patent for
which the patent claim for the patent (granted on 5 August 2023) reads as
follows: ‘The use of the compound (maxorevo) for the manufacture of a
medicament in an oral dosage form for the treatment of cardiac disorders for
administration no more than once daily for at least seven consecutive days,
where said compound has a plasma concentration half-life of 12 hours or less
when orally administered to a human patient, wherein the cardiac disorder is
arrhythmia, and wherein the oral dosage form is a rapid-release tablet.’ A
rival pharmaceutical firm, R.D. Gen, decides to apply for the revocation of
this patent to bring their own cardiac arrythmia medicine (which also makes
use of maxorevo) to market. The maxorevo compound was first identified in
March 2001. Outline the potentially viable revocation grounds that R.D. Gen
might rely on for this application and comment on the likelihood of success
for each ground.
To assess R.D. Gen’s grounds for revoking Pharmabayu Inc.’s patent in South Africa, it’s
necessary to consider the requirements for patentability under the South African Patents Act 57
of 1978 and applicable case law. The key grounds for revocation of a patent under section 61(1)
of the Patents Act include lack of novelty, lack of inventive step, non-patentable subject
matter, lack of utility, and prior use/disclosure.
Below is a structured analysis of the potentially viable revocation grounds that R.D. Gen might
rely upon and the likelihood of success for each.
1. Lack of Novelty – Section 61(1)(c)
Explanation: A patent lacks novelty if the invention was disclosed to the public anywhere in the
world before the priority date (in this case, before 5 August 2023, or the filing date).
Application to the Scenario:
The compound maxorevo was identified as early as March 2001.
It has been used in cardiac arrhythmia treatment since 2004.
